2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Monday, October 22, 2018

9:00AM-11:00AM: Abstract Number: 1179

Achieving Important Improvement in WOMAC Pain and Function By Three Months Post-Surgery Influences Satisfaction 1 Year Following Total Knee Replacement (TKR)

Health Services Research Poster II – ACR/ARHP

9:00AM-11:00AM: Abstract Number: 1655

Achieving Remission in Psoriatic Arthritis By Early Initiation of TNF Inhibition: A Double-Blind, Randomized, Placebo-Controlled Trial of Golimumab + Methotrexate Versus Placebo + Methotrexate

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

9:00AM-11:00AM: Abstract Number: 1157

Acknowledged Biostatistical Help and the Quality of Statistical Analyses in Randomized Controlled Trials in Rheumatology

Epidemiology and Public Health Poster II: Gout, Ankylosing Spondylitis, Osteoarthritis, Osteoporosis, Pain, and Function

9:00AM-11:00AM: Abstract Number: 1320

Activity Tracker Bracelets Captures Familial Mediterranean Fever Attacks and Their Impact on Daily Physical Activities

Miscellaneous Rheumatic and Inflammatory Diseases Poster II: Interstitial Lung Disease, Still's Disease, FMF, Polychondritis

9:00AM-11:00AM: Abstract Number: 1618

Adipose Tissue Inflammation in Psoriatic Arthritis: Overexpression of a Wide Array of Inflammatory Mediators and Associations with Disease and Treatment Characteristics

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

9:00AM-11:00AM: Abstract Number: 1424

After 24 Months Observation Period the Patients Related Outcomes Improve Significantly in the Juvenile Scleroderma Inceptions Cohorte

Pediatric Rheumatology – Clinical Poster II: Autoinflammatory Disorders, Scleroderma, and Miscellaneous

9:00AM-11:00AM: Abstract Number: 1044

Alendronate-CGS21680 Conjugates Prevent Bone Erosion in a Murine Osteolysis Model

Osteoarthritis and Joint Biology – Basic Science Poster I

9:00AM-11:00AM: Abstract Number: 1732

Alterations of Body Composition in Patients with Systemic Scleroderma Are Associated with Disease Activity, Physical Activity and Serum Levels of Inflammatory Cytokines

Systemic Sclerosis and Related Disorders – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1466

Altered Count of NK Cells and Non-Classical Monocyte Subpopulation in the Pre-Clinical Phase of Rheumatoid Arthritis

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

9:00AM-11:00AM: Abstract Number: 1553

An Analysis of Real-World Data on the Safety of Etanercept in Elderly Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Treatments Poster II: PROs, Safety and Comorbidity

9:00AM-11:00AM: Abstract Number: 1372

An Analysis of the Quality and Readability of Online Osteoarthritis Information with Historical Comparison

Osteoarthritis – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1757

An Economic Systematic Literature Review of Eosinophilic Granulomatosis with Polyangiitis

Vasculitis – ANCA-Associated Poster I

9:00AM-11:00AM: Abstract Number: 1028

An Entheseal Innate Immune Cell Biological Basis for Differential Efficacy of PDE4 and IL-23 Pathway Blockade between Psoriatic Disease and Rheumatoid Arthritis

Innate Immunity Poster

9:00AM-11:00AM: Abstract Number: 1250

An Evaluation of Utilization Patterns and Appropriateness of Laboratory Tests Among New Referrals to Rheumatologists: Choosing Unwisely!

Measures and Measurement of Healthcare Quality Poster II

9:00AM-11:00AM: Abstract Number: 1790

An Unmet Need for Oral Ulcer Activity in Patients with Behcet’s Disease: A Multi-National Study

Vasculitis Poster II: Behҫet’s Disease and IgG4-Related Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].